Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity

Central Hospital, Nancy, France101 enrolled

Overview

R2C2 study has shown that abdominal obesity is associated with a cardiac and vascular remodelling in healthy volunteers. This remodelling is correlated with renin-angiotensin aldosterone system (RAAS) activation and/or systemic fibrosis. R2C2 II study is designed to confirm the hypothesis that RAAS is associated with an early remodelling and implicated in the transition to cardiac failure in abdominal obesity.

Follow up of abdominal obesity patients from the R2C2 cohort study.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

101

Conditions

Obesity, Abdominal

Interventions

Urine sampleOTHER

dosages on one spot and 24h collection

Blood sampleOTHER

dosages

Assessment of sleep apnea syndromeOTHER

Electrocardiogram

Eligibility

Sex: ALLMin age: 43 YearsMax age: 72 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Being a former member of R2C2 study, abdominal obese group. * Having signed the informed consent (refusing to participate to the genetic study is not an exclusion criteria). * being affiliated to health insurance scheme. Inclusion Criteria of R2C2 study: * Men and women aged between 40 and 65 year's old * Caucasian * Born or living in France for at least 10 years * Presenting an abdominal obesity defined by a waist circumference \>94 cm in men and ≥ 80 cm in women, associated or not with untreated hypertension or hypertension treated for less than one year * Having signed the informed consent Exclusion Criteria: * Subjects unable to understand the information letter * Subjects under supervision or guardianship * pregnant or lactating woman * A contraindication to perform MRI is not an exclusion criteria.

Locations (1)

CIC-P - INSERM - Institut Lorrain du Cœur et des vaisseaux

Vandœuvre-lès-Nancy, Meurthe et Moselle, France

Outcomes

Primary Outcomes

cardiac extracellular matrix remodelling

Initial values of cardiac extracellular matrix remodelling biomarkers and the evolution of biomarkers at 3-7 years

Time frame: 3-7 years

Secondary Outcomes

Cardiac and arterial phenotype

Evolution of cardiac and vascular phenotype in 3-7 years.

Time frame: 3-7 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.